Skip to main content
Premium Trial:

Request an Annual Quote

BioNanomatrix and NCI Sign CRADA to Measure DNA Damage from Radiation Therapy

NEW YORK (GenomeWeb News) - Genome imaging company BioNanomatrix will work with the National Cancer Institute to develop technology to measure DNA damage caused by ionizing radiation therapy in cancer treatment, the company said last week.
Under the terms of the multi-year Cooperative Research and Development Agreement with NCI’s Radiation Biology Branch, BioNanomatrix will use its Nanoanalyzer as the basis of a system for quantifying the extent of DNA damage during treatment.
Han Cao, chief scientific officer of BioNanomatrix, said in a statement that physicians are currently "hindered in their efforts to deliver an optimal dose by a lack of information on the extent of damage to the patient from the radiation already administered."
The Nanoanalyzer uses a nanofluid array to unwind DNA into a linear form, which can be evaluated to identify specific DNA aberrations, BioNanomatrix said.
Financial terms of the agreement were not released.